Study EV-104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC)-Trial in progress.

被引：0
|
作者：
Kamat, Ashish M.
Steinberg, Gary D.
Allen Inman, Brant
Kates, Max R.
Uchio, Edward M.
Porten, Sima P.
Roupret, Morgan
Redorta, Joan
Catto, James W. F.
Kulkarni, Girish S.
Powles, Thomas
Tyson, Mark
Haas, Gabriel P.
Yu, Yao
Birrenkott, Matthew
Lotan, Yair
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] NYU, Perlmutter Canc Ctr, Dept Urol, New York, NY USA
[3] Duke Univ, Med Ctr, Durham, NC USA
[4] Johns Hopkins Med Ctr, Baltimore, MD USA
[5] Univ Calif Irvine, Irvine, CA USA
[6] Univ Calif San Francisco, San Francisco, CA USA
[7] Hop La Pitie Salpetriere, Paris, France
[8] Autonomous Univ Barcelona, Barcelona, Spain
[9] Sheffield Teaching Hosp, Sheffield, S Yorkshire, England
[10] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[11] Barts Canc Inst, London, England
[12] Mayo Clin Arizona, Phoenix, AZ USA
[13] Astellas Pharma Inc, Northbrook, IL USA
[14] Seagen Inc, Bothell, WA USA
[15] UT Southwestern Med Ctr, Dallas, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS582
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Study EV-104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC) (Trial in Progress)
    Kamat, A. M.
    Steinberg, G.
    Inman, B.
    Kates, M.
    Uchio, E.
    Porten, S.
    Rouperet, M.
    Palou, J.
    Catto, J.
    Kulkarni, G. S.
    Powles, T.
    Tyson, M.
    Haas, G.
    Ding, X.
    Narayanan, S.
    Lotan, Y.
    EUROPEAN UROLOGY, 2022, 81 : S507 - S507
  • [2] A first-in-human trial of intravesical enfortumab vedotin (EV), an antibody-drug conjugate (ADC), in patients with non-muscle invasive bladder cancer (NMIBC): Interim results of a phase 1 study (EV-104).
    Kamat, Ashish M.
    Lotan, Yair
    Roupret, Morgan
    Steinberg, Gary D.
    Inman, Brant A.
    Powles, Thomas
    Redorta, J. Palou
    Porten, Sima P.
    Kulkarni, Girish S.
    Uchio, Edward M.
    Gorla, Seema Rao
    Haas, Gabriel P.
    Yu, Yao
    Chia, Yen Lin
    Birrenkott, Matthew
    Kates, Max R.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] A phase I study of intravesical camrelizumab for BCG failure Non-Muscle Invasive Bladder Cancer (NMIBC)
    Wang, Y.
    Xu, P. H.
    Bian, X. J.
    Lu, X. L.
    Wang, Z.
    Wang, X.
    Yao, X. D.
    Shen, Y. J.
    Ye, D. Y.
    EUROPEAN UROLOGY, 2022, 81 : S251 - S251
  • [4] Phase 1 study of multi-dose administration of intravesical CG0070 in patients with non-muscle invasive bladder cancer (NMIBC)
    McKiernan, James M.
    Lamm, Donald L.
    Meng, Maxwell V.
    Nemunaitis, John J.
    Arseneau, James C.
    Stephenson, Joe
    Burke, James M.
    Aimi, Junko
    Maslyar, Daniel J.
    JOURNAL OF UROLOGY, 2008, 179 (04): : 616 - 616
  • [5] A phase I study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC).
    Woodcock, Victoria K.
    Purshouse, Karin
    Butcher, Chrissie
    Haddon, Caroline
    Verrall, Gillian
    Elhussein, Leena
    Salio, Mariolina
    Middleton, Mark R.
    Cerundolo, Vincenzo
    Crew, Jeremy
    Protheroe, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [6] Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer
    Molenaar, Remco J.
    van Hattum, Jons W.
    Brummelhuis, Iris S.
    Oddens, Jorg R.
    Savci-Heijink, C. Dilara
    Boeve, Egbert R.
    van der Meer, Saskia A.
    Witjes, J. Fred
    Pollak, Michael N.
    de Reijke, Theo M.
    Wilmink, Johanna W.
    BMC CANCER, 2019, 19 (01)
  • [7] Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer
    Remco J. Molenaar
    Jons W. van Hattum
    Iris S. Brummelhuis
    Jorg R. Oddens
    C. Dilara Savci-Heijink
    Egbert R. Boevé
    Saskia A. van der Meer
    J. Fred Witjes
    Michael N. Pollak
    Theo M. de Reijke
    Johanna W. Wilmink
    BMC Cancer, 19
  • [8] Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review
    Shelley, Mike D.
    Jones, Gabriel
    Cleves, Anne
    Wilt, Timothy J.
    Mason, Malcolm D.
    Kynaston, Howard G.
    BJU INTERNATIONAL, 2012, 109 (04) : 496 - 505
  • [9] Phase II trial of BC-819 intravesical gene therapy in combination with BCG in patients with non-muscle invasive bladder cancer (NMIBC).
    Halachmi, Sarel
    Leibovitch, Ilan
    Zisman, Amnon
    Stein, Avi
    Benjamin, Shalva
    Sidi, Ami
    Knickerbocker, Ron
    Limor, Michal
    Moore, Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [10] Phase I/II CANON study: oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21
    Pandha, H. S.
    Annels, N.
    Arif, M.
    Mostafid, H.
    Sandhu, S.
    Harrington, K.
    Melcher, A.
    Mansfield, D.
    Au, G.
    Grose, M.
    Karpathy, R.
    Shafren, D.
    ANNALS OF ONCOLOGY, 2016, 27
12345